# Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

> **NCT00345501** · PHASE2,PHASE3 · COMPLETED · sponsor: **Onassis Cardiac Surgery Centre** · enrollment: 208 (actual)

## Conditions studied

- Renal Insufficiency, Chronic
- Coronary Angiography
- Angioplasty, Transluminal, Percutaneous Coronary

## Interventions

- **DRUG:** Iloprost
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00345501
- **Lead sponsor:** Onassis Cardiac Surgery Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2007-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345501, "Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00345501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*